Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Scemblix
Pharma
Novartis' Scemblix leaps into newly diagnosed CML
The first-line nod marks an important step for the Gleevec follow-up on its way toward achieving the company's peak sales estimate of $3 billion.
Angus Liu
Oct 29, 2024 3:56pm
Takeda circles Ascentage's Scemblix challenger for up to $1.3B
Jun 14, 2024 11:30am
ASCO: Novartis' Scemblix proves benefits over Gleevec in CML
May 31, 2024 8:00am
Novartis gears up for key expansions of 3 cancer drugs
Apr 23, 2024 3:37pm
Regulatory tracker: Bayer adds new Kerendia CV outcomes nod
Aug 29, 2022 9:48am
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix
May 26, 2022 5:00pm
